Fei Sun

Fei Sun

Auto-generated profile, based on publicly available information

Fei Sun

Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin–Madison, Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in Cancer Research
Verified
Journal Article
Closed access
FSFei Sun
Fei Sun
KWKe Wang
Ke Wang
XDXingchen Dong
Xingchen Dong
HSHenry Secaira
Henry Secaira
AHAlisa Hui
Alisa Hui
TFTing Fu
Ting Fu
Bile acids (BA) not only influence the gut microbiome composition but are also metabolized by gut bacteria to form various microbial BAs. Among these, 3-oxo-lithocholic acid (3-oxo-LCA) and isoallo-LCA have been reported to modulate host immunity, suppress intestinal pathogens, and provide antiaging benefits, suggesting that they could also affect intestinal epithelial cells and colorectal cancer progression. To investigate the impact of 3-oxo-LCA on intestinal tumorigenesis, we evaluated its activity in vitro on mouse and human colorectal cancer cell lines, as well as primary mouse intestinal organoids and patient-derived colorectal cancer organoids, and in vivo using a genetically engineered mouse model, cell line–derived syngeneic and xenograft tumors, and patient-derived xenografts. 3-Oxo-LCA functioned as a potent FXR agonist that restored FXR signaling both in vitro and in vivo. Activation of FXR signaling reduced the growth of colorectal cancer cell lines and suppressed the proliferation of intestinal stem cells in both mouse organoids and patient-derived colorectal cancer organoids. In the APCMin/+ genetically engineered mouse model, 3-oxo-LCA reduced BA levels, enhanced gut barrier function, decreased tumor burden, and suppressed tumor initiation. Furthermore, 3-oxo-LCA significantly inhibited tumor progression in syngeneic and xenograft mouse models and promoted apoptosis within the tumors. Together, these results underscore the function of 3-oxo-LCA as an FXR agonist with the ability to inhibit colorectal cancer tumorigenesis and progression by modulating epithelial cell growth and death. Significance: The microbial bile acid 3-oxo-LCA activates FXR signaling in intestinal epithelial cells that inhibits cancer stem cell proliferation and induces apoptosis, highlighting the potential of 3-oxo-LCA for treating intestinal tumorigenesis.


15 December 2025
Verified
Other
Open access
FSFei Sun
Fei Sun
KWKe Wang
Ke Wang
XDXingchen Dong
Xingchen Dong
HSHenry Secaira
Henry Secaira
AHAlisa Hui
Alisa Hui
TFTing Fu
Ting Fu
3-oxo-LCA aberrantly elevated in obese but decreased in CRC mice models (and patients)

15 December 2025
Verified
Other
Open access
FSFei Sun
Fei Sun
KWKe Wang
Ke Wang
XDXingchen Dong
Xingchen Dong
HSHenry Secaira
Henry Secaira
AHAlisa Hui
Alisa Hui
TFTing Fu
Ting Fu
3-oxo-LCA decreases tumor load in MC38-xenograft C57BL/6 mice

15 December 2025
Verified
Other
Open access
FSFei Sun
Fei Sun
KWKe Wang
Ke Wang
XDXingchen Dong
Xingchen Dong
HSHenry Secaira
Henry Secaira
AHAlisa Hui
Alisa Hui
TFTing Fu
Ting Fu
3-oxo-LCA reshape the BAs pool in APCMin/+ mice

15 December 2025
Verified
Other
Open access
FSFei Sun
Fei Sun
KWKe Wang
Ke Wang
XDXingchen Dong
Xingchen Dong
HSHenry Secaira
Henry Secaira
AHAlisa Hui
Alisa Hui
TFTing Fu
Ting Fu
The effect of 3-oxo-LCA is FXR-dependent